US8039009 — Modified release formulations of memantine oral dosage forms
Method of Use · Assigned to Forest Laboratories Holdings ULC · Expires 2029-03-24 · 3y remaining
What this patent protects
This patent protects modified release formulations of memantine oral dosage forms that sustain the release of the active agent for 4 to 24 hours.
USPTO Abstract
The present invention provides pharmaceutical compositions given once daily containing at least one therapeutically active ingredient selected from the group consisting of memantine and a pharmaceutically acceptable salt of memantine, and a pharmaceutically acceptable polymeric matrix carrier. The dosage forms of the invention sustain the release of the therapeutically active agent from about 4 to about 24 hours when said dosage form is exposed to aqueous solutions. following entry of said form into a use environment, wherein said dosage form has a dissolution rate of more than about 80% after passage of about 6 hours to about 12 hours following said entry into said use environment.
Drugs covered by this patent
FDA Patent Use Codes
When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.
| Code | Description | Drug |
|---|---|---|
U-539 |
— | memantine-hydrochloride |
U-1641 |
— | donepezil-hydrochloride |
U-1641 |
— | donepezil-hydrochloride |
U-539 |
— | memantine-hydrochloride |
U-1641 |
— | donepezil-hydrochloride |
U-539 |
— | memantine-hydrochloride |
U-539 |
— | memantine-hydrochloride |
U-1641 |
— | donepezil-hydrochloride |
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.